Search
Heron Therapeutics Inc
HRTXAdd to Watchlist
0.438USD
+0.014+3.30%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
82.67MMarket Cap
LossP/E TTM
More Details of Heron Therapeutics Inc Company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Heron Therapeutics Inc Info
Ticker SymbolHRTX
Company nameHeron Therapeutics Inc
IPO dateAug 26, 1987
CEOCollard (Craig Alexander)
Number of employees122
Security typeOrdinary Share
Fiscal year-endAug 26
Address4242 Campus Point Court, Suite 200
CityCARY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18582514400
Websitehttps://www.herontx.com/
Ticker SymbolHRTX
IPO dateAug 26, 1987
CEOCollard (Craig Alexander)
Company Executives of Heron Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
737.39K
+25.04%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
250.05K
+3.58%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
221.55K
+5.64%
Mr. Mark Hensley
Mr. Mark Hensley
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
136.77K
+91.39%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
87.18K
-40.41%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
84.13K
+21.34%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
83.77K
-42.99%
Mr. Adam Morgan
Mr. Adam Morgan
Chairman of the Board
Chairman of the Board
60.31K
-44.01%
Mr. Michael Kaseta
Mr. Michael Kaseta
Independent Director
Independent Director
29.79K
-89.10%
Mr. Tom Cusack ,
Mr. Tom Cusack ,
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
737.39K
+25.04%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
250.05K
+3.58%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
221.55K
+5.64%
Mr. Mark Hensley
Mr. Mark Hensley
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
136.77K
+91.39%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
87.18K
-40.41%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
84.13K
+21.34%
FAQs
Who are the top five shareholders of Heron Therapeutics Inc?
The top five shareholders of Heron Therapeutics Inc are: Mr. Craig Alexander Collard
How many institutions hold shares of Heron Therapeutics Inc (HRTX)?
As of 2026Q1, 354 institutions hold shares of Heron Therapeutics Inc, with a combined market value of approximately 169.55M, accounting for 90.02% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -8087547.00.
What is the biggest source of revenue for Heron Therapeutics Inc?
In 2026Q1, the CINVANTI business generated the highest revenue for Heron Therapeutics Inc, amounting to 96.76M and accounting for 62.46% of total revenue.